Drug Delivery Strategies for Antivirals against Hepatitis B Virus.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
diarrhea 1 infectiousdiseases
hepatitis B 8 infectiousdiseases
hepatitis C 2 infectiousdiseases
lamivudine 4 infectiousdiseasesdrugs
ribavirin 1 infectiousdiseasesdrugs
tenofovir 3 infectiousdiseasesdrugs
AIDS 1 infectiousdiseases

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
lamivudine 2009 promised an enhanced effectiveness against HBV. Drugs such as interferon-α2B, PEGylated interferon-α2A, lamivudine , adefovir, tenofovir, entecavir, and telbivudine have all been recognized and acknowledged for their
lamivudine 33667 system showed a lack of adverse effects.Micelles were developed in one study for incorporating the lamivudine (LMV) prodrug LMV stearate. LMV stearate was synthesized to increase LMV lipophilicity, due to it being
lamivudine 53144 interferon-α/PEGylated-interferon/lambda-interferon; anti-HbeAg: anti-hepatitis B e-antigen; HCC: hepatocellular carcinoma; LMV: lamivudine ; ADV: adefovir dipivoxil; HBsAG: hepatitis B surface antigen; HCV: hepatitis C virus; LMV: lamivudine;
lamivudine 53246 lamivudine; ADV: adefovir dipivoxil; HBsAG: hepatitis B surface antigen; HCV: hepatitis C virus; LMV: lamivudine ; ALT: alanine aminotransferase; ADV: adefovir dipivoxil; ETV: entecavir; TDF: tenofovir disoproxil fumarate.viruses-10-00267-t002_Table
ribavirin 19017 chronic HCV, the administration of NTZ together with PEGylated IFN-α2a, with or without the addition of ribavirin , manifested the efficiency and acceptable safety of the thiazolide [[43],[44],[45]]. Together with the
tenofovir 2031 effectiveness against HBV. Drugs such as interferon-α2B, PEGylated interferon-α2A, lamivudine, adefovir, tenofovir , entecavir, and telbivudine have all been recognized and acknowledged for their treatment and direct
tenofovir 12311 seen in around 7% of patients after a six-month follow-up. A combination of NUC therapy (entecavir or tenofovir ) with recombinant human IL-7 (CYT107) or with both CYT107 and HBV vaccine (GenHevac B®, Pasteur, Merieux,
tenofovir 53335 virus; LMV: lamivudine; ALT: alanine aminotransferase; ADV: adefovir dipivoxil; ETV: entecavir; TDF: tenofovir disoproxil fumarate.viruses-10-00267-t002_Table 2Table 2Summary of anti-HBV thiazolide, siRNA, and HAP
Select Disease Character Offset Disease Term Instance
AIDS 18528 bacteria, protozoa, and helminths. NTZ antiviral exertion was first stumbled upon when patients with AIDS (coinfected with HBV or HCV) were being treated for cryptosporidial diarrhea, as it was the first thiazolide
diarrhea 18601 stumbled upon when patients with AIDS (coinfected with HBV or HCV) were being treated for cryptosporidial diarrhea , as it was the first thiazolide that was primarily used for the treatment of the protozoan Cryptosporidium
hepatitis B 710 yahya.choonara@wits.ac.za (Y.E.C.)Publication date (epub): 5/2018Publication date (collection): 5/2018AbstractChronic hepatitis B virus (HBV) infection poses a significant health challenge due to associated morbidity and mortality
hepatitis B 1588 their role in anti-HBV therapy.1. IntroductionA significant threat to patients suffering from chronic hepatitis B virus (HBV) infection lies in the emergence of cirrhosis, often leading to hepatocellular cancer, portal
hepatitis B 10852 mainstay cytokine presently utilized in the intervention of chronic HBV. Solely, it allows for anti- hepatitis B e-antigen (HBeAg) seroconversion in 25% of chronic HBV disease cases [[20],[21]]. Researchers examined
hepatitis B 11505 consequently, an improvement of liver histology. Future follow-ups showed a sustained clinical subsidence and hepatitis B surface antigen (HBsAG) seroconversion [[23],[24]]. Research has pointed out that lambda-λ has the
hepatitis B 51524 < 0.01 (reproduced with permission from [[95]]).viruses-10-00267-t001_Table 1Table 1Summary of anti- hepatitis B virus (HBV) cytokine and nucleot(s)ide analogue therapeutic agents as a treatment plan.Therapeutic AgentEffectiveness
hepatitis B 53085 HBsAg[[41],[42]]IFN-α/-PEG/-λ: interferon-α/PEGylated-interferon/lambda-interferon; anti-HbeAg: anti- hepatitis B e-antigen; HCC: hepatocellular carcinoma; LMV: lamivudine; ADV: adefovir dipivoxil; HBsAG: hepatitis
hepatitis B 53188 anti-hepatitis B e-antigen; HCC: hepatocellular carcinoma; LMV: lamivudine; ADV: adefovir dipivoxil; HBsAG: hepatitis B surface antigen; HCV: hepatitis C virus; LMV: lamivudine; ALT: alanine aminotransferase; ADV: adefovir
hepatitis B 54467 ribonucleic acids; RNA: ribonucleic acid; mRNA: messenger RNA; HAPs: heteroarylpyrimidines; HBcAg: hepatitis B core antigen
hepatitis C 11702 lambda-λ has the potential to be useful for therapeutic purposes in the alleviation of chronic HBV or hepatitis C virus (HCV) [[25]]. IFN-λ is similar to IFN-α and IFN-β in its antiviral behavior to inhibit HBV
hepatitis C 53222 hepatocellular carcinoma; LMV: lamivudine; ADV: adefovir dipivoxil; HBsAG: hepatitis B surface antigen; HCV: hepatitis C virus; LMV: lamivudine; ALT: alanine aminotransferase; ADV: adefovir dipivoxil; ETV: entecavir; TDF:

You must be authorized to submit a review.